Citation only
via Europe PMC
Brain glucose metabolism and blood brain barrier permeability in Alzheimer's disease continuum.
Ricci F, Motta C, Bonomi CG, Bernocchi F, Poli M, Koch G, Chiaravalloti A, Martorana A.
Aging · 2026
Abstract
<h4>Background</h4>Within the ATN framework of Alzheimer's disease (AD), patients are classified according to the presence of amyloid pathology (A), tau pathology (T), and neurodegeneration (N). While the A⁺T⁺N⁺ profile is well characterized, the A⁺T⁻N⁺ subgroup remains less understood. This phenotype may reflect mechanisms distinct from tau-driven pathology, potentially involving other amyloid co-pathology such as blood-brain barrier (BBB) dysfunction.<h4>Methods</h4>We examined A⁺T⁻N⁺ and A⁺T⁺N⁺ patients within the AD continuum (ADc) and cognitively healthy controls. All participants underwent cerebrospinal fluid (CSF) biomarker assessment and 18F-FDG positron emission tomography (FDG-PET). The CSF/serum albumin quotient (QAlb) was used as an index of BBB integrity. Voxel-wise multiple regression analyses evaluated associations between regional glucose metabolism and CSF biomarkers, QAlb, demographics, cognitive status, ApoE genotype, and vascular risk factors (Hypertension, Diabetes, and Hypercholesterolemia).<h4>Results</h4>Both AD subgroups showed hypometabolism in temporoparietal Default Mode Network regions. In ADc and A⁺T⁺N⁺ patients, posterior metabolism correlated positively with p-tau and negatively with t-tau. In A⁺T⁻N⁺ individuals, posterior hypometabolism was negatively associated with QAlb and positively with Aβ₄₂. Only Hypertension correlated with metabolism, involving the anterior cingulate cortex in ADc and A⁺T⁺N⁺, but not A⁺T⁻N⁺.<h4>Conclusions</h4>Within the AD continuum, A⁺T⁻N⁺ represent a subgroup of patients in whom FDG-PET metabolic dysfunctions appear to be associated with the coexistence of BBB dysfunction alongside amyloid pathology rather than tau-driven mechanisms.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.18632/aging.206393
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
F, R., C, M., CG, B., F, B., M, P., G, K., A, C., & A., M. (2026). Brain glucose metabolism and blood brain barrier permeability in Alzheimer's disease continuum. <em>Aging</em>. https://doi.org/10.18632/aging.206393
Vancouver
F R, C M, CG B, F B, M P, G K, et al. Brain glucose metabolism and blood brain barrier permeability in Alzheimer's disease continuum. Aging. 2026. doi:10.18632/aging.206393.
BibTeX
@article{ricci2026Braing,
title = {Brain glucose metabolism and blood brain barrier permeability in Alzheimer's disease continuum.},
author = {Ricci F and Motta C and Bonomi CG and Bernocchi F and Poli M and Koch G and Chiaravalloti A and Martorana A.},
journal = {Aging},
year = {2026},
doi = {10.18632/aging.206393},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in aging 2026
Open access · OA
Glycemic dysregulation and cognitive impairment in aging adults: a cross-sectional study with amyloid biomarker correlation.
Rejuvenation Research 2026
Citation only
Impact of Metformin on Healthspan-Related Outcomes and Incidence of Diseases of Aging in People with Type 2 Diabetes Mellitus: A Systematic Review
Rejuvenation research 2026
Citation only
Impact of Metformin on Healthspan-Related Outcomes and Incidence of Diseases of Aging in People with Type 2 Diabetes Mellitus: A Systematic Review.
Alzheimer s & Dementia 2022
Preprint · CC-BY
Distinct patterns of neurodegeneration after TBI and in Alzheimer’s disease
Alzheimer s Research & Therapy 2018
Open access · CC-BY
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
Annals of Neurology 2022
Open access · CC-BY